Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Neratinib

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

50%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 3 (1)

Trial Status

Recruiting1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06983691Not ApplicableRecruitingPrimary

Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib

NCT01808573Phase 3CompletedPrimary

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

Showing all 2 trials

Research Network

Common Treatments

  • Neratinib1
  • Lapatinib1
  • Patient Navigation Program1
  • Capecitabine1

Active Sponsors

  • Duke University1
  • Pfizer1
  • Puma Biotechnology, Inc.1

Top Investigators

Activity Timeline